ResearcherInsermActive in the last 2 years
Pierre‐Emmanuel Colombo
Matched on ORCID iD 0000-0002-0697-109X; OpenAlex author ID A5035202401. Sources: OpenAlex.
Their work
- Papers
- 11 (first author 1, last author 0)
- Trials
- 0
- Grants
- 0
- Labs led
- 0
- Collaborators
- 34
2014: 1 paper · 2015: none · 2016: none · 2017: none · 2018: 1 paper · 2019: 1 paper · 2020: 1 paper · 2021: 2 papers · 2022: none · 2023: none · 2024: 1 paper · 2025: 4 papers
Papers 11
- Is survival influenced by metastatic site in synchronous metastatic pancreatic adenocarcinoma (PDAC)? A prospective real-world BACAP study. Co-author DOI 10.1016/j.esmogo.2025.100144↗
- ATR inhibition potentiates FOLFIRINOX cytotoxic effect in models of pancreatic ductal adenocarcinoma by remodelling the tumour microenvironment. Co-author DOI 10.1038/s41416-024-02904-3↗
- Inhibiting microtubule polymerization with EAPB02303, a prodrug activated by catechol-O-methyl transferase, enhances paclitaxel effect in pancreatic cancer mod… Co-author DOI 10.1038/s41419-025-07747-1↗
- Prognosis Associated with Complete Pathological Response Following Neoadjuvant Treatment for PancreaTic AdenOcarciNOma in the FOFLIRINOX Era: the Multicenter T… Co-author DOI 10.1245/s10434-024-16735-2↗
- Predictive genomic and transcriptomic analysis on endoscopic ultrasound-guided fine needle aspiration materials from primary pancreatic adenocarcinoma: a prosp… Co-author DOI 10.1016/j.ebiom.2024.105373↗
- Anti-tumoral activity of the Pan-HER (Sym013) antibody mixture in gemcitabine-resistant pancreatic cancer models. Co-author DOI 10.1080/19420862.2021.1914883↗
- Distal Pancreatectomy with Celiac Axis Resection (Modified Appleby Procedure) and Arterial Reconstruction for Locally Advanced Pancreatic Adenocarcinoma After … Co-author DOI 10.1245/s10434-020-08740-y↗
- Incidence of Venous Thromboembolism in Patients With Newly Diagnosed Pancreatic Cancer and Factors Associated With Outcomes. Co-author DOI 10.1053/j.gastro.2019.12.009↗
- An auristatin-based antibody-drug conjugate targeting HER3 enhances the radiation response in pancreatic cancer. Co-author DOI 10.1002/ijc.32273↗
- Targeting the NRG1/HER3 pathway in tumor cells and cancer-associated fibroblasts with an anti-neuregulin 1 antibody inhibits tumor growth in pre-clinical model… First author DOI 10.1016/j.canlet.2018.06.023↗
- HER3 as biomarker and therapeutic target in pancreatic cancer: new insights in pertuzumab therapy in preclinical models. Co-author DOI 10.18632/oncotarget.2231↗
Closest collaborators
The 25 strongest of 34 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Christel Larbouret · 6 shared papers, 2014–2025 · strength 0.66
- Paper Inhibiting microtubule polymerization with EAPB02303, a prodrug activated by catechol-O-methyl transferase, enhances pa… DOI 10.1038/s41419-025-07747-1↗
- Paper ATR inhibition potentiates FOLFIRINOX cytotoxic effect in models of pancreatic ductal adenocarcinoma by remodelling the… DOI 10.1038/s41416-024-02904-3↗
- Paper Anti-tumoral activity of the Pan-HER (Sym013) antibody mixture in gemcitabine-resistant pancreatic cancer models. DOI 10.1080/19420862.2021.1914883↗
- Marine Bruciamacchie · 3 shared papers, 2021–2025 · strength 0.48
- Paper Inhibiting microtubule polymerization with EAPB02303, a prodrug activated by catechol-O-methyl transferase, enhances pa… DOI 10.1038/s41419-025-07747-1↗
- Paper ATR inhibition potentiates FOLFIRINOX cytotoxic effect in models of pancreatic ductal adenocarcinoma by remodelling the… DOI 10.1038/s41416-024-02904-3↗
- Paper Anti-tumoral activity of the Pan-HER (Sym013) antibody mixture in gemcitabine-resistant pancreatic cancer models. DOI 10.1080/19420862.2021.1914883↗
- Corinne Bousquet · 3 shared papers, 2018–2025 · strength 0.44
- Paper Inhibiting microtubule polymerization with EAPB02303, a prodrug activated by catechol-O-methyl transferase, enhances pa… DOI 10.1038/s41419-025-07747-1↗
- Paper ATR inhibition potentiates FOLFIRINOX cytotoxic effect in models of pancreatic ductal adenocarcinoma by remodelling the… DOI 10.1038/s41416-024-02904-3↗
- Paper Targeting the NRG1/HER3 pathway in tumor cells and cancer-associated fibroblasts with an anti-neuregulin 1 antibody inh… DOI 10.1016/j.canlet.2018.06.023↗
- Kévin Bigot · 2 shared papers, 2025 · strength 0.38
- Paper Inhibiting microtubule polymerization with EAPB02303, a prodrug activated by catechol-O-methyl transferase, enhances pa… DOI 10.1038/s41419-025-07747-1↗
- Paper ATR inhibition potentiates FOLFIRINOX cytotoxic effect in models of pancreatic ductal adenocarcinoma by remodelling the… DOI 10.1038/s41416-024-02904-3↗
- André Pèlegrin · 4 shared papers, 2014–2021 · strength 0.28
- Paper Anti-tumoral activity of the Pan-HER (Sym013) antibody mixture in gemcitabine-resistant pancreatic cancer models. DOI 10.1080/19420862.2021.1914883↗
- Paper An auristatin-based antibody-drug conjugate targeting HER3 enhances the radiation response in pancreatic cancer. DOI 10.1002/ijc.32273↗
- Paper Targeting the NRG1/HER3 pathway in tumor cells and cancer-associated fibroblasts with an anti-neuregulin 1 antibody inh… DOI 10.1016/j.canlet.2018.06.023↗
- Thierry Chardès · 4 shared papers, 2014–2021 · strength 0.28
- Paper Anti-tumoral activity of the Pan-HER (Sym013) antibody mixture in gemcitabine-resistant pancreatic cancer models. DOI 10.1080/19420862.2021.1914883↗
- Paper An auristatin-based antibody-drug conjugate targeting HER3 enhances the radiation response in pancreatic cancer. DOI 10.1002/ijc.32273↗
- Paper Targeting the NRG1/HER3 pathway in tumor cells and cancer-associated fibroblasts with an anti-neuregulin 1 antibody inh… DOI 10.1016/j.canlet.2018.06.023↗
- Christine Jean · 1 shared paper, 2025 · strength 0.19
- Lilian Schwartz · 1 shared paper, 2025 · strength 0.16
- Julie Navez · 1 shared paper, 2025 · strength 0.16
- Jonathan Garnier · 1 shared paper, 2025 · strength 0.16
- Charles de Ponthaud · 1 shared paper, 2025 · strength 0.16
- Mehdi El Amrani · 1 shared paper, 2025 · strength 0.16
- Sébastien Gaujoux · 1 shared paper, 2025 · strength 0.16
- Francois-Regis Souche · 1 shared paper, 2025 · strength 0.16
- Stéphanie Truant · 1 shared paper, 2025 · strength 0.16
- Emmanuel Buc · 1 shared paper, 2025 · strength 0.16
- Olivier Facy · 1 shared paper, 2025 · strength 0.16
- Alain Sauvanet · 1 shared paper, 2025 · strength 0.16
- Ugo Marchèse · 1 shared paper, 2025 · strength 0.16
- Pietro Addeo · 1 shared paper, 2025 · strength 0.16
- Alexandre Doussot · 1 shared paper, 2025 · strength 0.16
- Philippe Bachellier · 1 shared paper, 2025 · strength 0.16
- Mickaël Lesurtel · 1 shared paper, 2025 · strength 0.16
- Milena Muzzolini · 1 shared paper, 2025 · strength 0.16
- Christophe Laurent · 1 shared paper, 2025 · strength 0.16
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.